

Table 3. Summary of Natural History Study Mechanistic Samples for Participants that develop T1D at some point over Baseline or Follow-up
 (Incomplete Collection/Visit Hx Permissible*)

P2 (n=122); P3:6m (n=52); P3:12m (n=28); P3:18m (n=15) P3:24m (n=9); P3:30m (n=4); P3:36m (n=2)

Collection Phase*	Sample Type**	No. Subjects (% Row Total): <25%	No. Subjects (% Row Total): >=25%	No. Subjects (% Row Total): >=50%	Risk Missing	Total No. Subjects Submitting Sample (%)
Baseline	DNA	1 (1.3)	3 (4.0)	67 (89.3)	4 (5.3)	75 (61.5)
	HLA	4 (3.4)	4 (3.4)	102 (87.2)	7 (6.0)	117 (95.9)
	RNA	2 (3.0)	3 (4.5)	57 (86.4)	4 (6.1)	66 (54.1)
	PLASMA	1 (1.6)	3 (4.9)	54 (88.5)	3 (4.9)	61 (50.0)
	SERUM	2 (3.3)	3 (5.0)	52 (86.7)	3 (5.0)	60 (49.2)
	PBMC	1 (1.6)	3 (4.9)	53 (86.9)	4 (6.6)	61 (50.0)
Follow-up (6m)	RNA	2 (6.7)	2 (6.7)	25 (83.3)	1 (3.3)	30 (57.7)
	PLASMA	2 (6.9)	2 (6.9)	24 (82.8)	1 (3.4)	29 (55.8)
	SERUM	2 (7.1)	2 (7.1)	23 (82.1)	1 (3.6)	28 (53.8)
	PBMC	2 (7.1)	2 (7.1)	23 (82.1)	1 (3.6)	28 (53.8)
Follow-up (12m)	RNA	2 (11.1)	2 (11.1)	13 (72.2)	1 (5.6)	18 (64.3)
	PLASMA	2 (10.5)	2 (10.5)	14 (73.7)	1 (5.3)	19 (67.9)
	SERUM	2 (10.5)	2 (10.5)	14 (73.7)	1 (5.3)	19 (67.9)
	PBMC	2 (10.5)	2 (10.5)	14 (73.7)	1 (5.3)	19 (67.9)
Follow-up (18m)	RNA	1 (8.3)	1 (8.3)	10 (83.3)	. (.)	12 (80.0)
	PLASMA	1 (9.1)	1 (9.1)	9 (81.8)	. (.)	11 (73.3)
	SERUM	1 (9.1)	1 (9.1)	9 (81.8)	. (.)	11 (73.3)
	PBMC	1 (10.0)	1 (10.0)	8 (80.0)	. (.)	10 (66.7)
Follow-up (24m)	RNA	1 (11.1)	1 (11.1)	6 (66.7)	1 (11.1)	9 (100.0)
	PLASMA	1 (11.1)	1 (11.1)	6 (66.7)	1 (11.1)	9 (100.0)
	SERUM	1 (12.5)	1 (12.5)	5 (62.5)	1 (12.5)	8 (88.9)
	PBMC	1 (11.1)	1 (11.1)	6 (66.7)	1 (11.1)	9 (100.0)
Follow-up (30m)	RNA	. (.)	1 (33.3)	2 (66.7)	. (.)	3 (75.0)
	PLASMA	. (.)	1 (33.3)	2 (66.7)	. (.)	3 (75.0)
	SERUM	. (.)	1 (33.3)	2 (66.7)	. (.)	3 (75.0)
	PBMC	. (.)	1 (33.3)	2 (66.7)	. (.)	3 (75.0)
Follow-up (36m)	RNA	. (.)	1 (50.0)	1 (50.0)	. (.)	2 (100.0)
	PLASMA	. (.)	1 (50.0)	1 (50.0)	. (.)	2 (100.0)
	SERUM	. (.)	1 (50.0)	1 (50.0)	. (.)	2 (100.0)
	PBMC	. (.)	1 (50.0)	1 (50.0)	. (.)	2 (100.0)

* A subject enumerated in any Phase 3 visit is required to have had a Baseline (Phase 2) visit, although a subject doesn't necessarily need to have completed all prior P3 visits for inclusion in their latest P3 visit.

** All DNA samples collected -- across all visits herein (Baseline and any Phase 3 follow-up) -- are presented at Baseline. Note that a subject should have only provided one DNA sample, although it is possible multiple were provided.